Publications by authors named "Jennifer Couzin-Frankel"
An immune cell treatment that fights cancer is now taking aim at autoimmune disease.
View Article and Find Full Text PDFCo-authors say preliminary data on lecanemab fatalities don't support the paper's claims.
View Article and Find Full Text PDFClinicians and patients weigh modest benefits of the antibodies against sometimes-serious side effects.
View Article and Find Full Text PDFNew efforts seek causal links between pathogens and dementia.
View Article and Find Full Text PDFArticle Synopsis
- Eli Lilly's pivotal trial for donanemab, a drug aimed at treating Alzheimer's disease, raises concerns about how to effectively prescribe the medication.
- There are uncertainties regarding the ideal patient profiles and dosages needed to maximize benefits while minimizing potential risks.
- Further clarification and guidelines from the trial results are needed to ensure safe and effective use of donanemab in clinical practice.
New study questions often-implied benefit for participants.
View Article and Find Full Text PDFStudying cardiac effects of extreme exercise could yield clues to atrial fibrillation.
View Article and Find Full Text PDFNew Long Covid trials aim to clear lingering virus-and help patients in dire need.
View Article and Find Full Text PDFBlood tests can detect the disease process early, avoiding complications and aiding treatment.
View Article and Find Full Text PDFScientists divided over whether increased regulation would protect patients or limit access.
View Article and Find Full Text PDFBlockbuster weight loss drugs show promise for a wider range of health benefits.
View Article and Find Full Text PDFLimited data and lack of head-to-head studies make comparisons between shots tricky.
View Article and Find Full Text PDFSvetlana Mojsov helped discover the hormone GLP-1, paving the way for blockbuster obesity drugs. Now, she's fighting for recognition.
View Article and Find Full Text PDFArticle Synopsis
- Recent approvals for groundbreaking antibody treatments highlight progress in medical science.* -
- However, research into associated risks, like brain swelling and bleeding, is still not keeping pace.* -
- There’s an urgent need to focus on understanding these complications to ensure patient safety and improve treatment outcomes.*
Details emerge for uncommon cases of neurologic complications, blood pressure swings, and other side effects.
View Article and Find Full Text PDFConsensus grows for abandoning the ancestral strain to improve immune responses.
View Article and Find Full Text PDFA new procedure for donating hearts and other organs is saving lives. But for some it challenges the definition of death.
View Article and Find Full Text PDFArticle Synopsis
- Some scientists express concerns about the potential side effects of antiamyloid antibody drugs used for treating Alzheimer's disease.
- These concerns highlight the need for further research to understand the risks and benefits of these treatments.
- Ongoing studies aim to ensure patient safety and efficacy in using these drugs for neurological conditions.
Virus biology, widespread vaccination may be driving down risk of persistent symptoms.
View Article and Find Full Text PDFScientists and regulators seek new course amid uncertainty.
View Article and Find Full Text PDFArticle Synopsis
- The FDA has approved the use of a particular antibody treatment, indicating it may be beneficial for certain conditions.
- Despite this approval, there is ongoing controversy regarding the effectiveness and safety of the treatment.
- Different experts and stakeholders are actively discussing the potential risks and advantages associated with its use.